Brachytherapy News and Research

RSS

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platform

John J. Kresl, M.D., Ph.D., and colleagues at Banner Good Samaritan Medical Center are now treating a wide variety of cancers and neurological disorders with highly-accurate, non-invasive, image-guided radiosurgery using the Novalis Tx(TM) radiosurgery platform from Varian Medical Systems (NYSE: VAR) and BrainLAB.

4 Sep 2009

Nucletron announces financial results for the first half year of 2009

Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.

3 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

Varian Medical Systems is introducing the world's first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities for international cancer clinics. Varian's UNIQUE(TM) radiotherapy system is expected to make advanced care more affordable and more widely available to cancer patients around the world.

31 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Varian Medical Systems to equip a new proton therapy center in Sweden

Varian Medical Systems today announced it has been selected to equip a new proton therapy center in Sweden. In a ceremony conducted by Swedish authorities yesterday following a public tender, Varian was named to supply an estimated $60 million in products for Skandionkliniken, a new national proton therapy center owned by a consortium of seven of Sweden's counties.

20 Aug 2009

Seed implants suitable prostate cancer treatment for men of all ages

Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient.

3 Aug 2009

At VA hospital, a rogue cancer unit

The New York Times reports that a "rogue cancer unit" at a veteran's hospital in Philadelphia "operated with virtually no outside scrutiny and botched 92 of 116 [prostate] cancer treatments over a span of more than six years - and then kept quiet about it, according to interviews with investigators, government officials and public records."

22 Jun 2009

External beam partial breast irradiation most cost-effective treatment for women with early-stage breast cancer

External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

2 Jun 2009

Low oxygen levels in prostate tumors can predict recurrence

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.

17 May 2009

Radiation device in the breast reduces complications for early stage breast cancer patients

A new study shows that the SAVI™ applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices.

23 Apr 2009

Exposure to Agent Orange increases risk of aggressive recurrence of prostate cancer

Veterans exposed to Agent Orange are at increased risk of aggressive recurrence of prostate cancer, researchers report.

20 Apr 2009

High dosage brachytherapy obtains excellent results in head and neck tumors

High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation.

29 Mar 2009

Promising results for 5-day stereotactic body radiation therapy in early stage prostate cancer

Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments, according to a March 15 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology (ASTRO).

16 Mar 2009

Radioactive bone cement may be a new treatment option for breast cancer

For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission.

22 Feb 2009

First-degree family history of prostate cancer does not affect some treatment outcomes

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology.

5 Jan 2009

FDA grants compassionate case for use of novel wet age-related macular degeneration treatment

NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.